Jacobs Levy Equity Management, Inc Aptinyx Inc. Transaction History

Jacobs Levy Equity Management, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$2.93 - $4.3 $315,657 - $463,251	-107,733 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.05 - $4.99 $53,204 - $87,045	17,444 Added 19.32%	107,733 $364,000
Q2 2020 Aug 17, 2020	SELL	$1.99 - $4.4 $9,585 - $21,194	-4,817 Reduced 5.06%	90,289 $377,000
Q1 2020 May 15, 2020	SELL	$1.81 - $5.03 $166,022 - $461,376	-91,725 Reduced 49.1%	95,106 $205,000
Q4 2019 Feb 14, 2020	BUY	$2.84 - $4.25 $290,622 - $434,911	102,332 Added 121.1%	186,831 $639,000
Q3 2019 Nov 14, 2019	BUY	$3.0 - $4.08 $205,197 - $279,067	68,399 Added 424.84%	84,499 $295,000
Q2 2019 Aug 13, 2019	BUY	$2.95 - $4.38 $47,495 - $70,518	16,100 New	16,100 $54,000

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.